Advertisement
UK markets close in 5 hours 32 minutes
  • FTSE 100

    8,151.26
    -13.64 (-0.17%)
     
  • FTSE 250

    21,121.92
    -91.87 (-0.43%)
     
  • AIM

    786.60
    -0.38 (-0.05%)
     
  • GBP/EUR

    1.1917
    +0.0018 (+0.15%)
     
  • GBP/USD

    1.3042
    +0.0069 (+0.53%)
     
  • Bitcoin GBP

    50,100.21
    +1,673.41 (+3.46%)
     
  • CMC Crypto 200

    1,358.65
    +16.33 (+1.22%)
     
  • S&P 500

    5,667.20
    +35.98 (+0.64%)
     
  • DOW

    40,954.48
    +742.76 (+1.85%)
     
  • CRUDE OIL

    80.80
    +0.04 (+0.05%)
     
  • GOLD FUTURES

    2,477.90
    +10.10 (+0.41%)
     
  • NIKKEI 225

    41,097.69
    -177.39 (-0.43%)
     
  • HANG SENG

    17,739.41
    +11.43 (+0.06%)
     
  • DAX

    18,461.83
    -56.20 (-0.30%)
     
  • CAC 40

    7,554.92
    -25.11 (-0.33%)
     

Biogen's (NASDAQ:BIIB) investors will be pleased with their favorable 64% return over the last year

Passive investing in index funds can generate returns that roughly match the overall market. But you can significantly boost your returns by picking above-average stocks. To wit, the Biogen Inc. (NASDAQ:BIIB) share price is 64% higher than it was a year ago, much better than the market return of around 4.4% (not including dividends) in the same period. That's a solid performance by our standards! In contrast, the longer term returns are negative, since the share price is 0.5% lower than it was three years ago.

So let's assess the underlying fundamentals over the last 1 year and see if they've moved in lock-step with shareholder returns.

Check out our latest analysis for Biogen

To quote Buffett, 'Ships will sail around the world but the Flat Earth Society will flourish. There will continue to be wide discrepancies between price and value in the marketplace...' By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time.

ADVERTISEMENT

Biogen was able to grow EPS by 121% in the last twelve months. This EPS growth is significantly higher than the 64% increase in the share price. So it seems like the market has cooled on Biogen, despite the growth. Interesting.

The company's earnings per share (over time) is depicted in the image below (click to see the exact numbers).

earnings-per-share-growth
earnings-per-share-growth

We know that Biogen has improved its bottom line lately, but is it going to grow revenue? If you're interested, you could check this free report showing consensus revenue forecasts.

A Different Perspective

It's good to see that Biogen has rewarded shareholders with a total shareholder return of 64% in the last twelve months. That gain is better than the annual TSR over five years, which is 2%. Therefore it seems like sentiment around the company has been positive lately. Someone with an optimistic perspective could view the recent improvement in TSR as indicating that the business itself is getting better with time. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. For example, we've discovered 2 warning signs for Biogen that you should be aware of before investing here.

If you are like me, then you will not want to miss this free list of growing companies that insiders are buying.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here